Press releases

Interim report July 1- September 30, 2024

24 October, 2024

Summary of the first quarter (2024-07-01 – 2024-09-30) • Net sales amounted to MSEK 0,0 (0,0) • Operating profit/loss amounted to MSEK -1,3 (-1,1) • Earnings per share* SEK -0.06 […]


DexTech: Invitation to open Annual General Meeting and notice

26 September, 2024

On Thursday, October 31, 2024, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]


Dextech Medical AB Annual report 230701-240630

20 September, 2024

Download the annual report below. Annual report DexTech Medical AB 230701-240630


Year-end report July 1, 2023 – June 30, 2024

30 August, 2024

Summary of year-end report Fourth quarter (2024-04-01 – 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6 million (-1.3) Earnings per share* SEK -0.07 […]


DexTech Medical announces continued positive results from myeloma study

12 August, 2024

The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]


Interim report July 1, 2023 – March 31, 2024

26 April, 2024

Summary of the third quarter (2024-01-01 – 2024-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,5 (-1,6) Earnings per share* SEK -0.08 (-0.08) Summary of […]


DexTech Medical announces new positive results from the myeloma study

15 April, 2024

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]


Half-year report July 1 – December 31, 2023

15 February, 2024

Summary of the second quarter (2023-10-01 – 2023-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,4 (-1,2) Earnings per share* SEK -0,06 (-0.06) * Before […]


DexTech Medical announces positive results from the myeloma study

23 January, 2024

The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX). The baseline value for CTX decreases by […]


DexTech Medical informs about the myeloma study, the first patient is treated

13 December, 2023

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. […]